Rebon Pharmaceutical-B (09637): Full exercise of over-allotment rights, price stabilization actions, and end of price stabilization period

According to Zhitong Finance App, Libang Pharmaceutical-B (09637) announced that the co-representatives (for themselves and on behalf of the international underwriter) have exercised all of the over-allotment rights described in the prospectus on July 24, 2026 (Friday), involving a total of 8.513 million H shares, accounting for about 15% of the total number of shares available for subscription and sale under the global offering before any overallotment rights are exercised. The over-allotted shares will be issued and distributed by the company at HK$22.60 per H share. Over-allotted shares will be used to make up for overallocations in international offerings.

Pursuant to section 9 (2) of the Securities and Futures (Price Stabilization) Rules (Chapter 571W of the Laws of Hong Kong), the Company announced that the price stability period for the global offering ended on July 24, 2026 (Friday) (i.e. the 30th day after the deadline for submitting the Hong Kong Public Offer Application).